Literature DB >> 6479031

[Progressive systemic scleroderma. Clinical spectrum and prognostic parameters in 131 patients].

C Luderschmidt, I Kaulertz, G König, B Leisner.   

Abstract

The course of progressive systemic scleroderma was analysed from data collected on 131 patients. Classification was according to the extent of cutaneous involvement, type I (28%): sclerosis as far as the wrist-joint; type II (65%): sclerosis beyond the wrist-joint; type III (7%): sclerosis beginning to affect the trunk. In addition, they were subdivided into those with or without signs of systemic inflammation. The sex ratio was 3.5 females to 1 male. In half of the patients the disease manifested itself between the age of 30 and 50 years, with a clear peak about the 40th year. Serological evidence of inflammatory and immunological phenomena was present in nearly 50%, predominantly in those with type II or III. Oesophageal involvement was present in 84%, of the lung in 56% of all patients. ECG and echocardiographic changes were demonstrated in 34% of patients, while liver, intestines and kidneys were only rarely affected. The degree of organ involvement increased from type I to type III. Signs of systemic inflammation were predominantly associated with a clinically severe course.

Entities:  

Mesh:

Year:  1984        PMID: 6479031     DOI: 10.1055/s-2008-1069383

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Long-term manometry of tubular esophagus in progressive systemic sclerosis.

Authors:  R J Adamek; M Wegener; M Wienbeck; H Köhler; K Hoffmann; P Altmeyer
Journal:  Clin Investig       Date:  1994-05

2.  [An integrated method of pain measurement based on Tursky's pain perception profile, for use in patients with progressive systemic sclerosis.].

Authors:  O Berndt Scholz; I Curio
Journal:  Schmerz       Date:  1989-03       Impact factor: 1.107

3.  Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus.

Authors:  F Drenk; H Mensing; A Serbin; H Deicher
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.